Agenus Inc. (NASDAQ: AGEN) announced the first patient enrollment in its global phase 3 BATTMAN trial, evaluating the combination of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE